The decrease in GSH was also associated with the reduction of antioxidant capacity in CLL cells, both wt and mutant p53 cells, in the presence of PRIMA-1Met and SAS, reaching a minimum when the two treatments were combined (Figure 10B). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.